Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main page
Recent changes
Random page
Help about MediaWiki
Special pages
Surgopaedia
Search
Search
Appearance
Create account
Log in
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Editing
Hepatocellular carcinoma
(section)
Page
Discussion
English
Read
Edit
Edit source
View history
Tools
Tools
move to sidebar
hide
Actions
Read
Edit
Edit source
View history
General
What links here
Related changes
Page information
Appearance
move to sidebar
hide
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== '''Systemic therapy for metastatic/inoperable disease''' === * Overall rationale ** Traditional systemic chemotherapy has a poor outcome and doesn't help much, only a few months over best supportive care * First-line: ** Atezolizumab (PD-L1 inhibitor) + bevacizumab (VEGF inhibitor) ** Contraindicated in CP-B or C cirrhosis * Second-line: ** Sorafenib - tyrosine kinase inhibitor ** Immunotherapy - now a valid alternative to sorafenib, improved OS and QoL * Third-line: ** Regorafenib (multi-kinase inhibitor) - CP-A only ** Nivolumab (anti-PD-1 immune checkpoint inhibitor) - can be given in CP-B * No benefit to adjuvant chemotherapy to date although MAY be a role for sorafenib in high-risk patients after resection - phase II trial ongoing * Also no clear benefit to sorafenib along with regional therapy, although this decision is complex and patient-specific * IMBrave150 trial currently under way - sorafenib vs atezolizumab + bevacizumab, strong benefit to the latter, also better tolerated, will likely alter the treatment paradigm * Any disease progression is an indication to cease * Adjuvant therapy: ** Currently not recommended * Indications ** Advanced unresectable HCC ** Unable to deliver locoregional therapy ** Contraindicated in CP-B/C or ECOG 2/3/4
Summary:
Please note that all contributions to Surgopaedia may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Surgopaedia:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Search
Search
Editing
Hepatocellular carcinoma
(section)
Add topic